Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis
- Mingyao Sun; Honghao Lai; Feiyang Na; Sheng Li; Xia Qiu; Jinhui Tian
Access Resources
About
This study reviews monoclonal antibodies (mAbs) for preventing respiratory syncytial virus (RSV) in infants and children. It describes how nirsevimab, motavizumab, and palivizumab reduce RSV-related hospitalizations and infections. Motavizumab shows the most significant reduction in RSV infection rates compared to palivizumab. The study highlights the need for effective prevention due to RSV's impact on young children worldwide. While these mAbs show promise without increasing adverse events, more research is needed on safety and cost-effectiveness. Palivizumab is widely used but expensive; new options like nirsevimab are being developed for broader use.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.